Table III.
Association between BRAF V600E/TERT promoter mutation status and recurrences or distant metastasis in patients with papillary thyroid carcinoma.
| 1 vs. 2 | 1 vs. 3 | 2 vs. 3 | ||||||
|---|---|---|---|---|---|---|---|---|
| Mutation status | No. of recurrences or distant metastasis/no. patients | OR (95% CI) | P-value | OR (95% CI) | P-value | OR (95% CI) | P-value | |
| BRAF−/TERT− (1) | 1/34 | |||||||
| BRAF+/TERT− (2) | 4/169 | 0.800 (0.087-7.388) | 1.000 | 19.800 (1.707-129.643) | 0.018a | 24.750 (4.338-141.205) | 0.002a | |
| BRAF+/−/TERT+ (3) | 3/8 | |||||||
a
P<0.05. BRAF, B-Raf proto-oncogene; TERT, telomerase reverse transcriptase; OR, odds ratio.